CONTERA PHARMA A/S: Financial statements 2023
CVR: 33062214
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
CONTERA PHARMA A/S (CVR 33062214) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -58,993,909 and a net result of DKK -71,320,299 compared with DKK -56,868,331 the year before. Equity in the 2023 report amounted to DKK 86,298,042. The solvency ratio was 93.4%. The company had 17 employees in the financial year.
- Gross Profit
- DKK -58,993,909
- Profit/Loss
- DKK -71,320,299
- Equity
- DKK 86,298,042
- Total Assets
- DKK 92,368,576
- Employees
- 17
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -59 mio. | -71.3 mio. | 86.3 mio. | 17 |
| 2022 | - | -44.8 mio. | -56.9 mio. | 106.6 mio. | 14 |
| 2021 | - | -24.2 mio. | -31.5 mio. | 163.4 mio. | 13 |
| 2020 | - | -9.7 mio. | -12.3 mio. | 195 mio. | 4 |
| 2019 | - | -1.2 mio. | -2 mio. | 17.8 mio. | 1 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of November 17, 2023, WooHyun Lee has joined the board of directors of CONTERA PHARMA A/S.
As of November 17, 2023, Hee Won Yoo has left the board of directors of CONTERA PHARMA A/S.
As of November 16, 2023, WooHyun Lee has left the board of directors of CONTERA PHARMA A/S.
As of July 3, 2023, Jae Young Lee has joined the board of directors of CONTERA PHARMA A/S.
As of July 3, 2023, Sung Joon Kim has left the board of directors of CONTERA PHARMA A/S.
CONTERA PHARMA A/S has published its annual report for 2022. Gross profit came to DKK -44,831,824, and the net result was DKK -56,868,331.
As of February 9, 2023, Sun Ho Kim has left the board of directors of CONTERA PHARMA A/S.
About CONTERA PHARMA A/S
CONTERA PHARMA A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CONTERA PHARMA ApS and CONCIT PHARMA ApS. The management consists of Thomas Nikolaj Sager. The board consists of Jae Young Lee (chair), Jee Hun Kim, Paul Ejnar Gremaud Kristjansen and Thomas Nikolaj Sager. The company is owned by Bukwang Pharmaceutical Co., Ltd. The company has 1 employee (2018). In 2025, the company reported a gross profit of DKK 20,632,306 and a net result of DKK -4,783,781 compared with DKK -69,213,744 the year before. Equity in the 2025 report amounted to DKK 79,471,802.